Oral Low-Dose Ferric Citrate Is a Useful Iron Source for Hyperphosphatemic Hemodialysis Patients: A Case Series

Blood Purification

Volumn 43, Issue 1-3, 2017, Pages 97-100

  Tanemoto, Masayuki ^a   Ishimoto, Yu ^a   Saito, Hisako ^a  

^a Kuki General Hospital   (Japan)

Author keywords

Anemia; Ferric iron; Hemodialysis; Hyperphosphatemia; Iron deficiency

Indexed keywords

ANTIANEMIC AGENT; CALCIUM CARBONATE; FERRIC CITRATE; FERRITIN; HEMOGLOBIN; IRON; LANTHANUM CARBONATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATE BINDING AGENT; SEVELAMER; FERRIC ION; TRANSFERRIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPHOSPHATEMIA; IRON DEFICIENCY; IRON STORAGE; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; TRANSFERRIN BLOOD LEVEL; ADVERSE EFFECTS; BLOOD; DOSE RESPONSE;

DOSE-RESPONSE RELATIONSHIP, DRUG; FERRIC COMPOUNDS; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; HYPERPHOSPHATEMIA; IRON; RENAL DIALYSIS; TRANSFERRIN;

EID: 85006274908     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000450696     Document Type: Article

References (15)

1. Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH: An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant 2002;17:265-270.
2. Lee CT, Wu IW, Chiang SS, Peng YS, Shu KH, Wu MJ, Wu MS: Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study. J Nephrol 2015;28:105-113.
3. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP: Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol 2015;26:493-503.
4. Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma KN, Greene T, Lewis JB, Dwyer JP: Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol 2015;26:2578-2587.
5. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM: A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5. Am J Kidney Dis 2015;65:728-736.
6. Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T: 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010;14:240-275.
7. Horl WH: Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007;18:382-393.
8. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L: Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998;79:299-305.
9. Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI: An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997;48:34-40.
10. Wingard RL, Parker RA, Ismail N, Hakim RM: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995;25:433-439.
11. Fleming RE, Ponka P: Iron overload in human disease. N Engl J Med 2012;366:348-359.
12. Rao BS, Rao KS: Studies on the role of iron binding ligands and the intestinal brush border receptors in iron absorption. Indian J Biochem Biophys 1992;29:214-218.
13. Fishbane S, Mathew A, Vaziri ND: Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant 2014;29:255-259.
14. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB: Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis 2013;61:759-766.
15. Hsu CH, Patel SR, Young EW: New phosphate binding agents: ferric compounds. J Am Soc Nephrol 1999;10:1274-1280.